Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
I'm LongbridgeAI, I can summarize articles.William Blair analyst Lachlan Hanbury Brown maintained a Buy rating on Ocular Therapeutix (OCUL) on August 7, citing the differentiation of Axpaxli and supportive data from the competing LUGANO trial. He believes these factors bolster confidence in the lead asset's regulatory path. Additionally, Bank of America Securities reiterated a Buy rating with a $27 price target.
William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on OCUL stock, giving a Buy rating on August 7.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors that highlight Ocular Therapeutix’s competitive position in the tyrosine kinase inhibitor segment. He views the Axpaxli program as well differentiated, and believes recent LUGANO data from a competing product, while mixed, indirectly reinforce the therapeutic potential of TKIs in retinal disease.
He also notes that, despite a top-line miss on the primary endpoint in LUGANO, the underlying results still point to a real treatment effect, supporting the broader validity of the mechanism that underpins Axpaxli. In his view, this strengthens confidence in Ocular’s lead asset and its regulatory path, which, taken together with the stock’s reaction and risk‑reward profile, supports a positive recommendation on OCUL shares.
In another report released on August 7, Bank of America Securities also reiterated a Buy rating on the stock with a $27.00 price target.